NCT05587062View on ClinicalTrials.gov

Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration

PHASE3CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Age-Related Macular DegenerationNeovascular Age-related Macular Degeneration
Interventions
BIOLOGICAL

Aflibercept (CinnaGen Co, Iran)

Aflibercept (CinnaGen Co, Iran) by intravitreal injection

BIOLOGICAL

Aflibercept (Regeneron, USA)

Aflibercept (Regeneron, USA) by intravitreal injection

Trial Locations (1)

Unknown

Farabi Hospital, Tehran

Sponsors

Lead Sponsor

Cinnagen
All Listed Sponsors
lead

Cinnagen

INDUSTRY